Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Partial Identification of Amyloid-β Degrading Activity in Human Serum.

Mikawa R, Okuno A, Yoshimi T, Watanabe A, Maruyama M, Takikawa O.

Nagoya J Med Sci. 2019 Feb;81(1):55-64. doi: 10.18999/nagjms.81.1.55.

2.

Cyclic analogue of S-benzylisothiourea that suppresses kynurenine production without inhibiting indoleamine 2,3-dioxygenase activity.

Fukuda M, Sasaki T, Hashimoto T, Miyachi H, Waki M, Asai A, Takikawa O, Ohno O, Matsuno K.

Bioorg Med Chem Lett. 2018 Sep 15;28(17):2846-2849. doi: 10.1016/j.bmcl.2018.07.034. Epub 2018 Jul 20.

PMID:
30055888
3.

Plasma microRNA biomarker detection for mild cognitive impairment using differential correlation analysis.

Kayano M, Higaki S, Satoh JI, Matsumoto K, Matsubara E, Takikawa O, Niida S.

Biomark Res. 2016 Dec 12;4:22. doi: 10.1186/s40364-016-0076-1. eCollection 2016.

4.

New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation.

Coluccia A, Passacantilli S, Famiglini V, Sabatino M, Patsilinakos A, Ragno R, Mazzoccoli C, Sisinni L, Okuno A, Takikawa O, Silvestri R, La Regina G.

J Med Chem. 2016 Nov 10;59(21):9760-9773. Epub 2016 Oct 26.

PMID:
27690429
5.

The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway.

Wang D, Saga Y, Sato N, Nakamura T, Takikawa O, Mizukami H, Matsubara S, Fujiwara H.

Int J Oncol. 2016 Jun;48(6):2303-9. doi: 10.3892/ijo.2016.3486. Epub 2016 Apr 14.

6.

Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B.

Yoshio S, Sugiyama M, Shoji H, Mano Y, Mita E, Okamoto T, Matsuura Y, Okuno A, Takikawa O, Mizokami M, Kanto T.

Hepatology. 2016 Jan;63(1):83-94. doi: 10.1002/hep.28282. Epub 2015 Nov 23.

PMID:
26458241
7.

Affinity imaging mass spectrometry (AIMS): high-throughput screening for specific small molecule interactions with frozen tissue sections.

Yoshimi T, Kawabata S, Taira S, Okuno A, Mikawa R, Murayama S, Tanaka K, Takikawa O.

Analyst. 2015 Nov 7;140(21):7202-8. doi: 10.1039/c5an01381j.

PMID:
26365298
8.

Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.

Tanizaki Y, Kobayashi A, Toujima S, Shiro M, Mizoguchi M, Mabuchi Y, Yagi S, Minami S, Takikawa O, Ino K.

Cancer Sci. 2014 Aug;105(8):966-73. doi: 10.1111/cas.12445. Epub 2014 Jun 27.

9.

Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease.

Tajima Y, Ishikawa M, Maekawa K, Murayama M, Senoo Y, Nishimaki-Mogami T, Nakanishi H, Ikeda K, Arita M, Taguchi R, Okuno A, Mikawa R, Niida S, Takikawa O, Saito Y.

Lipids Health Dis. 2013 May 9;12:68. doi: 10.1186/1476-511X-12-68.

10.

NMR-based metabolomics of urine in a mouse model of Alzheimer's disease: identification of oxidative stress biomarkers.

Fukuhara K, Ohno A, Ota Y, Senoo Y, Maekawa K, Okuda H, Kurihara M, Okuno A, Niida S, Saito Y, Takikawa O.

J Clin Biochem Nutr. 2013 Mar;52(2):133-8. doi: 10.3164/jcbn.12-118. Epub 2013 Mar 1.

11.

Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors.

Tanaka M, Li X, Hikawa H, Suzuki T, Tsutsumi K, Sato M, Takikawa O, Suzuki H, Yokoyama Y.

Bioorg Med Chem. 2013 Mar 1;21(5):1159-65. doi: 10.1016/j.bmc.2012.12.028. Epub 2013 Jan 3.

PMID:
23337802
12.

Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection.

Higashitani K, Kanto T, Kuroda S, Yoshio S, Matsubara T, Kakita N, Oze T, Miyazaki M, Sakakibara M, Hiramatsu N, Mita E, Imai Y, Kasahara A, Okuno A, Takikawa O, Hayashi N, Takehara T.

J Gastroenterol. 2013 May;48(5):660-70. doi: 10.1007/s00535-012-0667-z. Epub 2012 Sep 14.

PMID:
22976933
13.

Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation.

Sato N, Saga Y, Mizukami H, Wang D, Takahashi S, Nonaka H, Fujiwara H, Takei Y, Machida S, Takikawa O, Ozawa K, Suzuki M.

Oncol Rep. 2012 Nov;28(5):1574-8. doi: 10.3892/or.2012.1984. Epub 2012 Aug 23.

14.

Identification of novel kynurenine production-inhibiting benzenesulfonamide derivatives in cancer cells.

Nakano S, Takai K, Isaka Y, Takahashi S, Unno Y, Ogo N, Matsuno K, Takikawa O, Asai A.

Biochem Biophys Res Commun. 2012 Mar 16;419(3):556-61. doi: 10.1016/j.bbrc.2012.02.059. Epub 2012 Feb 17.

PMID:
22369947
15.

Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy.

Wang D, Saga Y, Mizukami H, Sato N, Nonaka H, Fujiwara H, Takei Y, Machida S, Takikawa O, Ozawa K, Suzuki M.

Int J Oncol. 2012 Apr;40(4):929-34. doi: 10.3892/ijo.2011.1295. Epub 2011 Dec 13.

16.

Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface.

Blaschitz A, Gauster M, Fuchs D, Lang I, Maschke P, Ulrich D, Karpf E, Takikawa O, Schimek MG, Dohr G, Sedlmayr P.

PLoS One. 2011;6(7):e21774. doi: 10.1371/journal.pone.0021774. Epub 2011 Jul 6.

17.

Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO).

Croitoru-Lamoury J, Lamoury FM, Caristo M, Suzuki K, Walker D, Takikawa O, Taylor R, Brew BJ.

PLoS One. 2011 Feb 16;6(2):e14698. doi: 10.1371/journal.pone.0014698.

18.

Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion.

Nonaka H, Saga Y, Fujiwara H, Akimoto H, Yamada A, Kagawa S, Takei Y, Machida S, Takikawa O, Suzuki M.

Int J Oncol. 2011 Jan;38(1):113-20.

PMID:
21109932
19.

S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase.

Matsuno K, Takai K, Isaka Y, Unno Y, Sato M, Takikawa O, Asai A.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. doi: 10.1016/j.bmcl.2010.07.025. Epub 2010 Jul 11.

PMID:
20688518
20.

Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy.

Inaba T, Ino K, Kajiyama H, Shibata K, Yamamoto E, Kondo S, Umezu T, Nawa A, Takikawa O, Kikkawa F.

Gynecol Oncol. 2010 Jun;117(3):423-8. doi: 10.1016/j.ygyno.2010.02.028. Epub 2010 Mar 28.

PMID:
20350764
21.

Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of the CTLA-4/B7 and CCL22/CCR4 interactions.

Onodera T, Jang MH, Guo Z, Yamasaki M, Hirata T, Bai Z, Tsuji NM, Nagakubo D, Yoshie O, Sakaguchi S, Takikawa O, Miyasaka M.

J Immunol. 2009 Nov 1;183(9):5608-14. doi: 10.4049/jimmunol.0804116.

22.

Hemoglobin induces the expression of indoleamine 2,3-dioxygenase in dendritic cells through the activation of PI3K, PKC, and NF-kappaB and the generation of reactive oxygen species.

Ogasawara N, Oguro T, Sakabe T, Matsushima M, Takikawa O, Isobe K, Nagase F.

J Cell Biochem. 2009 Oct 15;108(3):716-25. doi: 10.1002/jcb.22308.

PMID:
19693771
23.

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.

Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O, Kikkawa F.

Gynecol Oncol. 2009 Nov;115(2):185-92. doi: 10.1016/j.ygyno.2009.07.015. Epub 2009 Aug 8.

PMID:
19665763
24.

Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells.

Brenk M, Scheler M, Koch S, Neumann J, Takikawa O, Häcker G, Bieber T, von Bubnoff D.

J Immunol. 2009 Jul 1;183(1):145-54. doi: 10.4049/jimmunol.0803277. Epub 2009 Jun 17.

25.

Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease.

Yamada A, Akimoto H, Kagawa S, Guillemin GJ, Takikawa O.

J Neurochem. 2009 Aug;110(3):791-800. doi: 10.1111/j.1471-4159.2009.06175.x. Epub 2009 May 18.

26.

Free iron ions decrease indoleamine 2,3-dioxygenase expression and reduce IFNgamma-induced inhibition of Chlamydia trachomatis infection.

Krausse-Opatz B, Wittkop U, Gutzki FM, Schmidt C, Jürgens-Saathoff B, Meier S, Beckmann B, Takikawa O, Morgan MA, Tsikas D, Stichtenoth DO, Wagner AD, Zeidler H, Köhler L.

Microb Pathog. 2009 Jun;46(6):289-97. doi: 10.1016/j.micpath.2009.03.001. Epub 2009 Mar 21.

PMID:
19306922
27.

Indoleamine 2,3-dioxygenase expression and regulation in chronic periodontitis.

Nisapakultorn K, Makrudthong J, Sa-Ard-Iam N, Rerkyen P, Mahanonda R, Takikawa O.

J Periodontol. 2009 Jan;80(1):114-21. doi: 10.1902/jop.2009.080315 .

PMID:
19228097
28.

Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.

Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O, Isobe K, Kikkawa F.

Clin Cancer Res. 2008 Nov 15;14(22):7251-9. doi: 10.1158/1078-0432.CCR-08-0991.

29.

Infection of myeloid dendritic cells with Listeria monocytogenes leads to the suppression of T cell function by multiple inhibitory mechanisms.

Popov A, Driesen J, Abdullah Z, Wickenhauser C, Beyer M, Debey-Pascher S, Saric T, Kummer S, Takikawa O, Domann E, Chakraborty T, Krönke M, Utermöhlen O, Schultze JL.

J Immunol. 2008 Oct 1;181(7):4976-88.

30.

Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival.

Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O, Kikkawa F.

Clin Cancer Res. 2008 Apr 15;14(8):2310-7. doi: 10.1158/1078-0432.CCR-07-4144.

31.

High-affinity uptake of kynurenine and nitric oxide-mediated inhibition of indoleamine 2,3-dioxygenase in bone marrow-derived myeloid dendritic cells.

Hara T, Ogasawara N, Akimoto H, Takikawa O, Hiramatsu R, Kawabe T, Isobe K, Nagase F.

Immunol Lett. 2008 Feb 15;116(1):95-102. doi: 10.1016/j.imlet.2007.11.016. Epub 2007 Dec 26.

PMID:
18179826
32.

Diazotization of kynurenine by acidified nitrite secreted from indoleamine 2,3-dioxygenase-expressing myeloid dendritic cells.

Hara T, Yamakura F, Takikawa O, Hiramatsu R, Kawabe T, Isobe K, Nagase F.

J Immunol Methods. 2008 Mar 20;332(1-2):162-9. Epub 2007 Dec 17.

PMID:
18158157
33.

Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.

Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W.

Clin Cancer Res. 2007 Dec 1;13(23):6993-7002.

34.

Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation?

Scheler M, Wenzel J, Tüting T, Takikawa O, Bieber T, von Bubnoff D.

Am J Pathol. 2007 Dec;171(6):1936-43. Epub 2007 Nov 30.

35.

Characterization of the kynurenine pathway in human neurons.

Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, Takikawa O, Brew BJ.

J Neurosci. 2007 Nov 21;27(47):12884-92.

36.

Impact of foetus and mother on IFN-gamma-induced indoleamine 2,3-dioxygenase and inducible nitric oxide synthase expression in murine placenta following Toxoplasma gondii infection.

Pfaff AW, Mousli M, Sénégas A, Marcellin L, Takikawa O, Klein JP, Candolfi E.

Int J Parasitol. 2008 Feb;38(2):249-58. Epub 2007 Jul 26.

PMID:
17822706
37.

Astrocyte indoleamine 2,3-dioxygenase is induced by the TLR3 ligand poly(I:C): mechanism of induction and role in antiviral response.

Suh HS, Zhao ML, Rivieccio M, Choi S, Connolly E, Zhao Y, Takikawa O, Brosnan CF, Lee SC.

J Virol. 2007 Sep;81(18):9838-50. Epub 2007 Jul 11.

38.

[Chronic fatigue syndrome and neurotransmitters].

Miwa S, Takikawa O.

Nihon Rinsho. 2007 Jun;65(6):1005-10. Review. Japanese.

PMID:
17561689
39.

Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide.

Thomas SR, Terentis AC, Cai H, Takikawa O, Levina A, Lay PA, Freewan M, Stocker R.

J Biol Chem. 2007 Aug 17;282(33):23778-87. Epub 2007 May 29.

40.

OCTN2VT, a splice variant of OCTN2, does not transport carnitine because of the retention in the endoplasmic reticulum caused by insertion of 24 amino acids in the first extracellular loop of OCTN2.

Maekawa S, Mori D, Nishiya T, Takikawa O, Horinouchi T, Nishimoto A, Kajita E, Miwa S.

Biochim Biophys Acta. 2007 Jun;1773(6):1000-6. Epub 2007 Apr 19.

41.

Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.

Takao M, Okamoto A, Nikaido T, Urashima M, Takakura S, Saito M, Saito M, Okamoto S, Takikawa O, Sasaki H, Yasuda M, Ochiai K, Tanaka T.

Oncol Rep. 2007 Jun;17(6):1333-9.

PMID:
17487387
42.
43.

Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer.

Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, Saito S.

Cancer Sci. 2007 Jun;98(6):874-81. Epub 2007 Apr 13.

44.

Upregulation of placental indoleamine 2,3-dioxygenase by human chorionic gonadotropin.

Lei ZM, Yang M, Li X, Takikawa O, Rao CV.

Biol Reprod. 2007 Apr;76(4):639-44. Epub 2006 Dec 20.

PMID:
17182891
45.

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.

Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, Nagasaka T, Takikawa O, Kikkawa F.

Br J Cancer. 2006 Dec 4;95(11):1555-61. Epub 2006 Nov 21.

46.

Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2.

Nagai K, Takikawa O, Kawakami N, Fukao M, Soma T, Oda A, Nishiya T, Hayashi M, Lu L, Nakano M, Kajita E, Fujita H, Miwa S.

Arch Biochem Biophys. 2006 Aug 1;452(1):29-37. Epub 2006 Jun 21.

47.

Inhibition of indoleamine 2,3 dioxygenase activity by H2O2.

Poljak A, Grant R, Austin CJ, Jamie JF, Willows RD, Takikawa O, Littlejohn TK, Truscott RJ, Walker MJ, Sachdev P, Smythe GA.

Arch Biochem Biophys. 2006 Jun 1;450(1):9-19. Epub 2006 Mar 20.

PMID:
16624246
48.

IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion.

Miwa N, Hayakawa S, Miyazaki S, Myojo S, Sasaki Y, Sakai M, Takikawa O, Saito S.

Mol Hum Reprod. 2005 Dec;11(12):865-70. Epub 2006 Jan 18.

PMID:
16421220
49.

Nitration and inactivation of IDO by peroxynitrite.

Fujigaki H, Saito K, Lin F, Fujigaki S, Takahashi K, Martin BM, Chen CY, Masuda J, Kowalak J, Takikawa O, Seishima M, Markey SP.

J Immunol. 2006 Jan 1;176(1):372-9.

50.

Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.

Wingender G, Garbi N, Schumak B, Jüngerkes F, Endl E, von Bubnoff D, Steitz J, Striegler J, Moldenhauer G, Tüting T, Heit A, Huster KM, Takikawa O, Akira S, Busch DH, Wagner H, Hämmerling GJ, Knolle PA, Limmer A.

Eur J Immunol. 2006 Jan;36(1):12-20.

Supplemental Content

Loading ...
Support Center